Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus
Marcel A. van de Ree, Menno Volkert Huisman, H. M. G. Princen et al. · Atherosclerosis · 2002
Cited by 159 works. doi:10.1016/s0021-9150(02)00316-7
Authors
References
- C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women
- Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction
- Production of C-reactive protein and risk of coronary events in stable and unstable angina
- Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels
- The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
- Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
- C-Reactive Protein Adds to the Predictive Value of Total and HDL Cholesterol in Determining Risk of First Myocardial Infarction
- PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
- Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses
- Elevated C-Reactive Protein Levels in Overweight and Obese Adults